Involvment of cytosolic and mitochondrial GSK-3β in mitochondrial dysfunction and neuronal cell death of MPTP/MPP+-treated neurons

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Petit Paitel, Agnès ^a   Brau, Frédéric ^a   Cazareth, Julie ^a   Chabry, Joëlle ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CASPASE 3; CASPASE 9; GLYCOGEN SYNTHASE KINASE 3BETA; KENPAULLONE; LITHIUM CHLORIDE; SMALL INTERFERING RNA; TYROSINE; 1 METHYL 4 PHENYLPYRIDINIUM; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MITOCHONDRIAL PROTEIN;

ADULT ANIMAL; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL FRACTIONATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DEPOLARIZATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; RNA INTERFERENCE; WESTERN BLOTTING; ANIMAL; APOPTOSIS; BRAIN; C57BL MOUSE; CELL CULTURE; CELL LINE; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MITOCHONDRION; MOUSE; NERVE CELL; PHYSIOLOGY;

RODENTIA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BRAIN; CELL FRACTIONATION; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; CYTOSOL; FLOW CYTOMETRY; GLYCOGEN SYNTHASE KINASE 3; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NEURONS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 65549123313     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005491     Document Type: Article

References (70)

1. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5: 525-535.
2. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, et al. (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1: 1269.
3. Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, et al. (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163: 1450-1455.
4. Parker WD Jr, Boyson SJ, Parks JK (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719-723.
5. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889-909.
6. Vila M, Przedborski S (2003) Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4: 365-375.
7. Perier C, Tieu K, Guegan C, Caspersen C, Jackson-Lewis V, et al. (2005) Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A 102: 19126-19131.
8. Roucou X, Martinou JC (2001) Conformational change of Bax: a question of life or death. Cell Death Differ 8: 875-877.
9. Embi N, Rylatt DB, Cohen P (1980) Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107: 519-527.
10. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95-102.
11. Muyllaert D, Kremer A, Jaworski T, Borghgraef P, Devijver H, et al. (2008) Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology? Genes Brain Behav 7 Suppl 1: 57-66.
12. Avila J, Hernandez F (2007) GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother 7: 1527-1533.
13. Iqbal K, Grundke-Iqbal I (2008) Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med 12: 38-55.
14. Doble BW, Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186.
15. Martinez A, Castro A, Dorronsoro I, Alonso M (2002) Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 22: 373-384.
16. Maiese K, Chong ZZ, Shang YC (2007) Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem 14: 1729-1738.
17. Lee KY, Koh SH, Noh MY, Park KW, Lee YJ, et al. (2007) Glycogen synthase kinase-3beta activity plays very important roles in determining the fate of oxidative stress-inflicted neuronal cells. Brain Res 1129: 89-99.
18. Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65: 391-426.
19. Wang W, Yang Y, Ying C, Li W, Ruan H, et al. (2007) Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 52: 1678-1684.
20. King TD, Bijur GN, Jope RS (2001) Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res 919: 106-114.
21. Youdim MB, Arraf Z (2004) Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46: 1130-1140.
22. Chen G, Bower KA, Ma C, Fang S, Thiele CJ, et al. (2004) Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. Faseb J 18: 1162-1164.
23. King TD, Jope RS (2005) Inhibition of glycogen synthase kinase-3 protects cells from intrinsic but not extrinsic oxidative stress. Neuroreport 16: 597-601.
24. Lai JS, Zhao C, Warsh JJ, Li PP (2006) Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur J Pharmacol 539: 18-26.
25. Hoshi M, Sato M, Kondo S, Takashima A, Noguchi K, et al. (1995) Different localization of tau protein kinase I/glycogen synthase kinase-3 beta from glycogen synthase kinase-3 alpha in cerebellum mitochondria. J Biochem 118: 683-685.
26. Bijur GN, Jope RS (2003) Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport 14: 2415-2419.
27. Ohori K, Miura T, Tanno M, Miki T, Sato T, et al. (2008) Ser9 phosphorylation of mitochondrial GSK-3beta is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant-induced apoptosis. Am J Physiol Heart Circ Physiol 295: H2079-2086.
28. Hetman M, Cavanaugh JE, Kimelman D, Xia Z (2000) Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci 20: 2567-2574.
29. Feng J, Lucchinetti E, Ahuja P, Pasch T, Perriard JC, et al. (2005) Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3beta. Anesthesiology 103: 987-995.
30. Park SS, Zhao H, Mueller RA, Xu Z (2006) Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. J Mol Cell Cardiol 40: 708-716.
31. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M (2008) Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 117: 2761-2768.
32. Zhou K, Zhang L, Xi J, Tian W, Xu Z (2009) Ethanol prevents oxidant-induced mitochondrial permeability transition pore opening in cardiac cells. Alcohol Alcohol 44: 20-24.
33. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, et al. (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76: 1265-1274.
34. Dirikoc S, Priola SA, Marella M, Zsurger N, Chabry J (2007) Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity. J Neurosci 27: 9537-9544.
35. Przedborski S, Tieu K, Perier C, Vila M (2004) MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 36: 375-379.
36. Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2: 141-151.
37. Orth M, Tabrizi SJ (2003) Models of Parkinson's disease. Mov Disord 18: 729-737.
38. Stambolic V, Ruel L, Woodgett JR (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6: 1664-1668.
39. Kunick C, Lauenroth K, Leost M, Meijer L, Lemcke T (2004) 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett 14: 413-416.
40. Das S, Wong R, Rajapakse N, Murphy E, Steenbergen C (2008) Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation. Circ Res 103: 983-991.
41. Schapira AH (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 7: 97-109.
42. Keeney PM, Xie J, Capaldi RA, Bennett JP Jr (2006) Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26: 5256-5264.
43. Beal MF (2005) Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 58: 495-505.
44. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, et al. (1996) Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 40: 663-671.
45. Senatorov VV, Ren M, Kanai H, Wei H, Chuang DM (2004) Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease. Mol Psychiatry 9: 371-385.
46. Bijur GN, De Sarno P, Jope RS (2000) Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem 275: 7583-7590.
47. Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, et al. (2004) Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp Cell Res 297: 186-196.
48. Wu Y, Shang Y, Sun S, Liang H, Liu R (2007) Erythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis via the Akt/ GSK-3beta/caspase-3 mediated signaling pathway. Apoptosis 12: 1365-1375.
49. Bijur GN, Jope RS (2001) Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem 276: 37436-37442.
50. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, et al. (2003) Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem 278: 48872-48879.
51. Takadera T, Ohyashiki T (2004) Glycogen synthase kinase-3 inhibitors prevent caspase-dependent apoptosis induced by ethanol in cultured rat cortical neurons. Eur J Pharmacol 499: 239-245.
52. Bijur GN, Jope RS (2003) Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation. J Neurochem 87: 1427-1435.
53. Beurel E, Jope RS (2006) The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79: 173-189.
54. Linseman DA, Butts BD, Precht TA, Phelps RA, Le SS, et al. (2004) Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci 24: 9993-10002.
55. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR (2006) Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749-760.
56. Obame FN, Plin-Mercier C, Assaly R, Zini R, Dubois-Rande JL, et al. (2008) Cardioprotective effect of morphine and a blocker of glycogen synthase kinase 3 beta, SB216763 [3-(2,4-dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrrole-2, 5-dione], via inhibition of the mitochondrial permeability transition pore. J Pharmacol Exp Ther 326: 252-258.
57. Nishihara M, Miura T, Miki T, Tanno M, Yano T, et al. (2007) Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol 43: 564-570.
58. Lizcano JM, Alessi DR (2002) The insulin signalling pathway. Curr Biol 12: R236-238.
59. Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, et al. (2004) In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 29: 1426-1431.
60. Nonaka S, Hough CJ, Chuang DM (1998) Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 95: 2642-2647.
61. Nonaka S, Katsube N, Chuang DM (1998) Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine. J Pharmacol Exp Ther 286: 539-547.
62. Chen RW, Chuang DM (1999) Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 274: 6039-6042.
63. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA, et al. (1999) Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J Clin Psychiatry 60 Suppl 2: 27-39; discussion 40-21, 113-116.
64. Chuang DM, Chen RW, Chalecka-Franaszek E, Ren M, Hashimoto R, et al. (2002) Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 4: 129-136.
65. Manji HK, Chen G (2002) PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry 7 Suppl 1: S46-56.
66. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, et al. (2008) Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 28: 2576-2588.
67. Mishra R, Barthwal MK, Sondarva G, Rana B, Wong L, et al. (2007) Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3. J Biol Chem 282: 30393-30405.
68. Takadera T, Fujibayashi M, Kaniyu H, Sakota N, Ohyashiki T (2007) Caspase-dependent apoptosis induced by thapsigargin was prevented by glycogen synthase kinase-3 inhibitors in cultured rat cortical neurons. Neurochem Res 32: 1336-1342.
69. Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK (2004) Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 9: 734-755.
70. Rowe MK, Chuang DM (2004) Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med 6: 1-18.